Search

An 88-year- old man with small lymphocytic lymphoma presented to the hospital with shortness of breath and was diagnosed with heart failure. Serial blood cultures and echocardiography revealed Staphylococcus epidermidis endocarditis, complicated by severe aortic regurgitation. Despite intravenous antibiotic therapy and aggressive intravenous diuresis therapy in the hospital, he decompensated into cardiogenic shock, requiring invasive haemodynamic monitoring and inotrope therapy. With multidisciplinary discussion involving the patient and his children, there was a joint decision that at his advanced age, he would not pursue surgical aortic valve replacement and instead proceed with a transcatheter aortic valve replacement (TAVR) with palliative intent. He underwent TAVR with subsequent symptomatic and functional improvement as well as resolution of cardiogenic shock. [ABSTRACT FROM AUTHOR]

A 63‐year‐old man with congenital bicuspid aortic valve disease and complex surgical history (that includes a Ross procedure complicated by cardiac arrest requiring emergency coronary artery bypass graft surgery, multiple subsequent sternotomies to treat a failed pulmonic homograft and pseudoaneurysm repair of the left and right ventricular outflow tracts (LVOT/RVOT), bioprosthetic aortic valve replacement, and aortic valve endocarditis) presented with worsening heart failure symptoms secondary to bioprosthetic aortic valve failure and recurrent pulmonic valve stenosis successfully treated with transcatheter intervention. [ABSTRACT FROM AUTHOR]

The article describes a case study of randomized trial of the Guaginig Responsiveness with A VeryNow assay- Impact on Thrombosis And Safety (GRAVITAS) on patients treated with high-dose clopidogrel after percutaneous coronary intervention (PCI). The study shows that patients given 600- milligram (mg) initial dose and 150 mg daily dose for six months did not reduce death incidence caused by cardiovascular disease, stent thrombosis or nonfatal myocardial infarction than those patients given the standard dose of 75 mg daily.

Aims: The aim of this study was to determine whether platelet reactivity on clopidogrel therapy, as measured by a point-of-care platelet function assay, is associated with thrombotic events after percutaneous coronary intervention (PCI) with drug-eluting stents (DESs). [ABSTRACT FROM PUBLISHER]